Form 4: Baker Bros. Advisors Report Beneficial Ownership Changes in BeiGene, Ltd.

Baker Bros. Advisors and related entities report changes in beneficial ownership of BeiGene, Ltd. ordinary shares and share options due to grants of restricted stock units and share options to their employees serving as BeiGene directors.

Summary

• Baker Bros. Advisors LP, along with related entities and individuals, filed a Form 4 detailing changes in beneficial ownership of BeiGene, Ltd. securities.
• The report covers transactions occurring on May 21, 2025.
• The transactions primarily involve the grant of restricted stock units (RSUs) and share options to Michael Goller and Ranjeev Krishana, who are full-time employees of Baker Bros. Advisors LP and serve as directors of BeiGene.
• Each of Goller and Krishana received 10,985 RSUs and 22,750 share options.
• The RSUs vest on the earlier of the first anniversary of the grant date or the date of the next annual general meeting of BeiGene.
• The share options have an exercise price of $18.19 and vest on the earlier of May 21, 2026, or the date of the next annual general meeting of BeiGene.
• The report also reflects the indirect beneficial ownership of ordinary shares and American Depositary Shares (ADS) held by various Baker Bros. entities, including 667, L.P. and Baker Brothers Life Sciences, L.P.
• Julian C. Baker and Felix J. Baker may be deemed to have an indirect pecuniary interest in these securities due to their ownership interest in the general partners of these funds.
• The filing clarifies that Baker Bros. Advisors LP disclaims beneficial ownership of the securities held by the Funds except to the extent of their pecuniary interest therein.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing, but the continued investment by Baker Bros. Advisors suggests a positive outlook on BeiGene's prospects. The grants of RSUs and share options to directors are a positive sign of alignment.

Positives

• The grant of RSUs and share options to directors aligns their interests with those of the company and shareholders.
• The vesting schedules for the RSUs and share options incentivize long-term performance and commitment.

Future Outlook

The document does not contain specific forward-looking statements regarding BeiGene's future performance, but the grants of RSUs and share options suggest an expectation of continued growth and value creation.

Management Comments

• Michael Goller and Ranjeev Krishana serve on the Board as representatives of the Funds and their affiliates and control persons.
• By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer.

Industry Context

Baker Bros. Advisors is a well-known investment firm specializing in the biotechnology industry, and their holdings in BeiGene reflect their investment strategy in the sector. Changes in their ownership positions are often monitored by other investors as an indicator of confidence in the company's prospects.

Comparison to Industry Standards

• The vesting schedules and terms of the RSUs and share options appear to be fairly standard for director compensation in publicly traded biotech companies.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also use equity-based compensation to align director and shareholder interests.
• The specific amounts and vesting terms would need to be compared to peer companies to determine if they are above or below average.

Stakeholder Impact

• The grants of RSUs and share options could positively impact shareholder value if BeiGene's stock price increases.
• The directors are incentivized to make decisions that benefit the company and its shareholders.

Key Dates

Keywords

BeiGene, Baker Bros. Advisors, Beneficial Ownership, Form 4, RSUs, Share Options, Directors, Securities, ADS